Association between Decreased Kidney Function and Endotoxin Receptor CD14 C-159T Polymorphism among Japanese Health Check-up Examinees

REFERENCES

• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1)S1–S266
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–2169
   PubMed Web of Science ®Google Scholar
• Baldini M, Lohman IC, Halonen M, et al. A polymorphism*in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20: 976–983
   PubMed Web of Science ®Google Scholar
• Kabesch M, Hasemann K, Schickinger V, et al. A promoter polymorphism in the CD14 gene is associated with elevated levels of soluble CD14 but not with IgE or atopic diseases. Allergy 2004; 59: 520–525
   PubMed Web of Science ®Google Scholar
• Loppnow H, Stelter F, Schonbeck U, et al. Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14. Infect Immun 1995; 63: 1020–1026
   Google Scholar
• Unkelbach K, Gardemann A, Kostrzewa M, et al. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999; 19: 932–938
   PubMed Web of Science ®Google Scholar
• Nishimura S, Zaitsu M, Hara M, et al. A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. J Pediatr 2003; 143: 357–362
   PubMed Web of Science ®Google Scholar
• Hamajima N, Saito T, Matsuo K, et al. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res 2000; 91: 865–868
   PubMedGoogle Scholar
• Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247–254
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int 2005; 67: 1216–1233
   PubMed Web of Science ®Google Scholar
• LeVan TD, Bloom JW, Bailey TJ, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2001; 167: 5838–5844
   PubMed Web of Science ®Google Scholar
• Gazouli M, Mantzaris G, Kotsinas A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005; 11: 681–685
   PubMed Web of Science ®Google Scholar
• Risley P, Jerrard-Dunne P, Sitzer M, et al. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: The Carotid Atherosclerosis Progression Study (CAPS). Stroke 2003; 34: 600–604
   Google Scholar
• Losito A, Kalidas K, Santoni S, et al. Association of the -159C/T polymorphism of the endotoxin receptor (CD14) with carotid artery disease and cardiovascular mortality in dialysis patients. Blood Purif 2005; 23: 128–133
   Google Scholar
• Yoon HJ, Shin JH, Yang SH, et al. Association of the CD14 gene-159C polymorphism with progression of IgA nephropathy. J Med Genet 2003; 40: 104–108
   PubMedGoogle Scholar
• Amar J, Ruidavets JB, Bal dit Sollier C, et al. CD14 C(-260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. J Hypertens 2004; 22: 1523–1528
   Google Scholar
• Vercelli D. Learning from discrepancies: CD14 polymorphisms, atopy and the endotoxin switch. Clin Exp Allergy 2003; 33: 153–155
   PubMed Web of Science ®Google Scholar
• Ushiyama C, Nakamura T, Suzuki S, et al. Effect of mizoribine on serum IgE concentration in patients with IgA nephropathy. Nephron 2001; 87: 194–195
   Google Scholar
• Nakada TA, Hirasawa H, Oda S, et al. Influence of toll-like receptor 4, CD14, tumor necrosis factor, and interleukine-10 gene polymorphisms on clinical outcome in Japanese critically ill patients. J Surg Res 2005; 129: 322–328
   Google Scholar
• McCullough PA, Jurkovitz CT, Pergola PE, et al. for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167: 1122–1129
   PubMedGoogle Scholar
• Rahman M, Pressel S, Davis BR, et al. ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172–180
   PubMed Web of Science ®Google Scholar
• Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1–12
   PubMed Web of Science ®Google Scholar
• Morrissey J, Guo G, McCracken R, et al. Induction of CD14 in tubular epithelial cells during kidney disease. J Am Soc Nephrol 2000; 11: 1681–1690
   Google Scholar
• Scherberich JE, Nockher WA. Blood monocyte phenotypes and soluble endotoxin receptor CD14 in systemic inflammatory diseases and patients with chronic renal failure. Nephrol Dial Transplant 2000; 15: 574–578
   PubMedGoogle Scholar